|Awarded On||February 18, 2015|
|Title||Counteracting tumor evasion of antibody immunity by a novel therapeutic strategy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Zhiqiang An|
|Cancer Sites||All Sites|
The natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employing the latest anti-cancer monoclonal antibodies, would reasonably be expected to suppress tumor growth. Yet, a perplexing resistance to both is widespread. The ineffectiveness of the immune system to prevail in these situations suggests that cancers possess tactics to evade antibodies that could otherwise eradicate them. With a clinical context in mind, we observed that tumor-associated protein-degrading enzymes can diminish, and in some cases negate, cell killing functions by inducing a single clip in a small part of the antibody structure. The structural modification is so subtle ...